Psychogenics: August 2007 & January 2015
Sunovion and PsychoGenics Inc. entered into a research collaboration to use PschoGenics’ SmartCube™ technology to develop proprietary compounds for psychiatric disorders.
“Our collaboration with Sunovion is highly productive and rewarding as we interact with some of the best minds and creative scientists in drug discovery. There are also several earlier-stage programs for other CNS indications in Sunovion’s popeline that further validate our phenotypic approach to cns drug discovery,” PychoGenics President & CEO Emer Leahy, Ph.D. remarked.
Elevation Pharmaceuticals and PARI: August 2012
Sunovion acquired Elevation Pharmaceuticsl, Inc., a privately held biopharmaceutical company specializing in the development of new aerosol therapies for patients with moderate to severe chronic obstructive pulmonary disease (COPD).
“Patients are at the heart of everything we do,” Sunovion Executive Vice President, Chief Medical Officer, Head of Global Clinical Development Antony Loebel, M.D. said. “This is an important milestone for us and the larger respiratory community, as we continue our mission of pioneering innovative treatments and therapies for COPD patients, their caregivers and health care providers.”
Sunovion acquired Cynapsus Therapeutics Inc. for its product candidate, APL–130277, which is designed to be a fast-acting, on-demand treatment option for managing OFF episodes associated with Parkinson’s disease.
“With its leadership in therapies for central nervous system disorders and commercial experience specific to neurology, we believe Sunovion is best suited to advance APL–130277 in the United States and other key markets,” Cynapsus President and CEO Anthony J. Giovinazzo said.
Empatica: December 2016
Sunovion will initiate recruitment for an Aptiom® (eslicarbazepine acetate) clinical study using integrated digital health technology to aid seizure detection. We will be the first to use the investigational Embrace watch by Empatica Inc. to aid in partial-onset seizure detection during an anti-epileptic drug clinical trial.
“We believe that incorporating digital health technologies into traditional treatment paradigms has the potential to inform and enhance best practices and further empower people living with serious medical conditions and their families,” Sunovion Executive Vice President, Chief Medical Officer, Head of Global Clinical Development Antony Loebel, M.D. said. “We look forward to sharing the results of this study and continue to look for opportunities for Sunovion to leverage advances in digital health.”
Sunovion signed a licensing agreement with Novartis for the U.S. commercial rights to its three treatments for chronic obstructive pulmonary disease (COPD: Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Seebri™ Neohaler® (glycopyrrolate) inhalation powder, and Arcapta® Neohaler® (indacaterol) inhalation powder.
“Given the evolving market dynamics, we believe these products will have the greatest impact in the U.S. when commercialized by a company with an established presence in the COPD field,” Novartis Pharmaceuticals Corporation President Fabrice Chouraqui said.